Cell Tribune
CellTribune.com provides business and research news updates for the cell and gene therapy industry. CellTribune follows the companies and people who drive innovation in this exciting technology. The goal of CellTribune is to be recognized as the media leader and the go-to source for originally-reported, quality news coverage in this industry. We strive to become the link between budding companies, analysts and institutional investors. Submit your press release to Cell Tribune for immediate publication.
Abeona Receives FDA Regenerative Medicine Advanced Therapy Designation for EB-101 Gene...
NEW YORK and CLEVELAND, Jan. 29, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare...
CAR-T cell therapy benefits limited to few patients because of ‘Insurance...
Two CAR T-cell therapies has now been approved in the United States ― tisagenlecleucel (Kymriah, Novartis), for certain pediatric and young adult patients who have a...
GBT Receives FDA Breakthrough Therapy Designation for Voxelotor for Treatment of...
SOUTH SAN FRANCISCO, Calif., Jan. 09, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy...
GenCure Opens BioManufacturing Center for Large-Scale Production of Adult Stem Cells...
San Antonio, Texas, Jan. 10, 2018 (GLOBE NEWSWIRE) --
GenCure, a subsidiary of BioBridge Global, today opened the first phase of a new biomanufacturing center...
‘Decorated’ Stem Cells Could Offer Targeted Heart Repair
Although cardiac stem cell therapy is a promising treatment for heart attack patients, directing the cells to the site of an injury – and...
Dynamk Capital Invests in FloDesign Sonics, a Game-Changer for Cell Therapy
ENGLEWOOD CLIFFS, N.J., Jan. 10, 2018 /PRNewswire/ -- Dynamk Capital, a life sciences venture capital fund, today announced an exciting new investment in advancing the commercial...
FDA Clears Pluristem’s Expanded Access Program to Initiate Treatments of Critical...
HAIFA, ISRAEL, January 9, 2018 -- Pluristem Therapeutics Inc. (NASDAQ: PSTI, TASE: PSTI), a leading developer of placenta-based cell therapy products, announced today that...
American CyroStem Warned by FDA to Stop Using Stem Cell Therapy...
American CryoStem has received a warning letter from the U.S. Food and Drug Administration (FDA) for marketing its adipose-derived stem cell product Atcell without required regulatory approval,...
Celixir’s cell therapy gets green light for heart failure trial
The Medicines and Healthcare Products Regulatory Agency has issued a green light allowing Celixir to carry out a potentially pivotal Phase IIb human clinical...
Cancer immune therapy developed from ‘miraculous’ recovery patients
A new immune therapy developed from “miraculous” cases of cancer recovery could be tested on human patients next year. The treatment uses cancer-killing immune...
